Wall Street Zen Downgrades Aveanna Healthcare (NASDAQ:AVAH) to Buy

Aveanna Healthcare (NASDAQ:AVAH) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Several other equities research analysts have also recently weighed in on the stock. UBS Group upped their price objective on shares of Aveanna Healthcare from $8.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday. Stephens raised shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $10.00 to $11.00 in a report on Friday, May 15th. Raymond James Financial boosted their target price on shares of Aveanna Healthcare from $13.00 to $15.00 and gave the company a “strong-buy” rating in a research report on Friday. Barclays upped their price target on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.78.

Aveanna Healthcare Price Performance

Aveanna Healthcare stock opened at $12.32 on Friday. The firm has a market cap of $2.69 billion, a PE ratio of 10.02, a price-to-earnings-growth ratio of 1.22 and a beta of 1.90. The company has a debt-to-equity ratio of 4.47, a current ratio of 1.16 and a quick ratio of 1.16. The stock’s fifty day moving average price is $8.97 and its two-hundred day moving average price is $7.75. Aveanna Healthcare has a one year low of $5.93 and a one year high of $12.52.

Aveanna Healthcare (NASDAQ:AVAH) last released its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. The firm had revenue of $670.48 million during the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. As a group, research analysts expect that Aveanna Healthcare will post 0.68 EPS for the current fiscal year.

Insider Activity at Aveanna Healthcare

In other Aveanna Healthcare news, major shareholder J.H. Whitney Equity Partners V sold 5,842,240 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $6.24, for a total value of $36,455,577.60. Following the sale, the insider owned 13,450,547 shares in the company, valued at $83,931,413.28. This trade represents a 30.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Patrick A. Cunningham sold 125,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $7.59, for a total value of $948,750.00. Following the sale, the insider owned 212,755 shares in the company, valued at $1,614,810.45. This represents a 37.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 31,305,664 shares of company stock valued at $215,555,910 in the last quarter. 5.30% of the stock is owned by company insiders.

Institutional Trading of Aveanna Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in AVAH. Caitong International Asset Management Co. Ltd increased its stake in shares of Aveanna Healthcare by 252.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after buying an additional 2,400 shares during the period. C M Bidwell & Associates Ltd. acquired a new stake in Aveanna Healthcare during the 2nd quarter worth approximately $69,000. Summit Securities Group LLC acquired a new stake in Aveanna Healthcare during the 1st quarter worth approximately $53,000. Quantbot Technologies LP bought a new stake in Aveanna Healthcare during the 2nd quarter worth approximately $43,000. Finally, Freestone Grove Partners LP bought a new stake in Aveanna Healthcare during the 2nd quarter worth approximately $73,000. 87.96% of the stock is currently owned by institutional investors.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations. Revenue increased 13.7% year over year to $670.5 million, while net income rose to $40.3 million from $27.0 million. Adjusted EBITDA reached $95.4 million, up 8.0%, and adjusted EPS of $0.22 topped analyst estimates of $0.19. Aveanna Healthcare Second Quarter Financial Results and Revised 2026 Guidance
• Positive Sentiment: Management raised full-year guidance. Aveanna now expects 2026 revenue above $2.68 billion, compared with its previous $2.63 billion-$2.65 billion range, and adjusted EBITDA above $365 million, up from $338 million-$342 million. The company cited reimbursement improvements, preferred-payer relationships and continued demand for complex home care. AVAH Q2 Earnings Call Highlights Higher Growth Targets
• Positive Sentiment: Analysts lifted their price targets. BMO Capital Markets raised its target from $10 to $14 and maintained an “outperform” rating. UBS raised its target from $8 to $13, although it retained a “neutral” rating. The revisions signal improved earnings expectations and support the stock’s recent strength. Benzinga analyst price target updates
• Neutral Sentiment: Growth is concentrated in Private Duty Services, which generates roughly 83% of revenue. Rapid revenue expansion is offsetting pressure on gross margins across business segments, making margin trends an important focus for investors. Aveanna Healthcare Q2 Earnings Report

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.